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Background: Adjuvant endocrine therapy can improve disease-free survival and time before recurrence in breast
cancer patients. However, it is associated with considerable side effects that negatively affect patients’ quality of life
and cause non-adherence. The recently demonstrated effect of individual expectations on side-effect development
(nocebo effect) suggests that psychological factors play a role in the prevention of side effects. The aim of this
study is to evaluate cognitive-behavioral side-effect prevention training (SEPT) for breast cancer patients. This article
describes the study protocol and applied research methods.
Methods/Design: In a randomized controlled trial, 184 female breast cancer patients are assigned to receive either
SEPT, standard medical care or a manualized supportive therapy at the start of adjuvant endocrine treatment. SEPT
consists of three sessions of cognitive-behavioral training including psychoeducation to provide a realistic view of
endocrine therapy, imagination-training to integrate positive aspects of medication into daily life, and side-effect
management to enhance expectations about coping ability. Side effects three months after the start of endocrine
therapy serve as primary outcomes. Secondary outcomes include quality of life, coping ability and patients’
medication adherence. Patients’ expectations (i.e., expectations about side effects, coping ability, treatment and
illness) are analyzed as mediators.
Discussion: The optimization of expectations might be a potential pathway in health care to improve patients’
quality of life during long-term medication intake. The results will provide implications for a possible integration of
evidence-based prevention training into clinical practice.
Trial registration: ClinicalTrials.gov, (NCT01741883).
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Endocrine therapy is the pivotal adjuvant treatment for
over 75% of breast cancer patients. National and inter-
national guidelines recommend it for long-term intake,
over at least five years, in patients with hormone-recep-
tor-positive primary breast cancer [1,2]. Adjuvant endo-
crine therapy reduces the risk of cancer recurrence,
development of metastases, and cancer mortality [3,4].
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distribution, and reproduction in any mediumdiscontinues treatment [5], while another 17% refuse to
initiate drug intake [6]. Reported non-adherence rates
range from 35% to 50% [7,8], leading to increased mor-
tality in women with breast cancer [9]. Main reasons for
non-adherence are side effects that reduce patients’
quality of life [10]. Thus, effective side-effect manage-
ment and side-effect prevention are crucial.
Most frequently reported side effects of endocrine
therapy are arthralgia, hot flushes, weight gain, mood
swings, loss of libido and vaginal dryness [11,12]. To a
great extent these symptoms are directly caused by the
pharmacodynamics of the treatment, depleting womened Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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to typical menopausal discomforts. In contrast, long-
term evaluations of adjuvant hormonal therapy showed
that a substantial proportion of the reported side effects
were not related to the treatment [13]. These side ef-
fects, such as headaches, skin irritation, dizziness, nausea
and gastrointestinal irritation, have no known pharma-
cological association with endocrine treatment and are
therefore termed non-specific medication side effects
[14]. They are influenced by patient characteristics such
as expectations and pre-existing symptoms. It is assumed
that analog processes are involved in the nocebo (Latin:
“I shall harm”) phenomenon, in which placebo-pills cause
adverse effects [15]. Hence, a randomized placebo-con-
trolled study of letrozole showed that around 20% of
breast cancer patients in the placebo arm experienced
typical menopausal symptoms [16]. Thus, negative expec-
tations can not only influence the occurrence of non-
specific side effects but even worsen specific side effects
via the nocebo-mechanism (nocebo effect) [17,18].
Negative expectations about medication have been
shown to predict the incidence of non-specific side
effects in patients with rheumatoid arthritis, even if
disease severity and medication regimen were controlled
[19]. Expectations about occurrence and intensity of side
effects seem to be an important predictor of side effects
in cancer treatment [20], for example chemotherapy-
related nausea [21]. A recent meta-analysis showed a
significant, medium-sized association between patients’
expectations of side effects and the actual experience of
these side effects from cancer treatments [22]. In a pilot
study by our group, response expectations predicted the
incidence of side effects three months after the start of
endocrine treatment [23,24]. Furthermore, cognitive rep-
resentations and expectations about the consequences of
illness were found to be associated with physical health
outcomes in breast cancer patients [25]. Leventhal’s
self-regulation model of health [26] additionally focuses
on expected coping with illness [27] and the emotional
representations of an illness [26]. Thus, anxiety [28] and
depression may be relevant in the development of
nocebo effects and non-specific side effects [14]. Several
other factors appear to be of importance in this context:
e.g., prior experiences with side effects [22], higher
pre-existing symptoms [29], and the tendency toward
somatization, symptom amplification and selective atten-
tion on bodily sensations [14], all of which can result in
a possible misinterpretation of prior existing symptoms
as side effects of the cancer medication [30]. Taken to-
gether, patients’ expectations seem to be essential for the
development of side effects. Optimizing these expecta-
tions might be a promising way to minimize patients’
side-effect burden during long-term intake of endocrine
medication.Only few studies have tried to optimize expectations in
cancer treatment. Changes in illness representations are
associated with less fear of progression [31], and patients
with high expectations for treatment-induced nausea
could profit from a positive expectation-manipulation
[32]. In particular, the way information about side effects
is given to the patients is crucial for the development of
expectations. It is recommended that information be
framed in a positive way, e.g., not only explain possible
side effects but also the expected benefits of the medica-
tion. Further, it is important to promote a positive doctor-
patient interaction and to foster effective management of
symptoms [33]. Recent studies showed that cognitive
behavioral therapy helps breast cancer patients in the
management of menopausal side effects and can lead to
decreased levels of reported symptoms [34,35]. So far, no
study has focused on optimizing expectations to prevent
side effects. We therefore developed a psychological side-
effect prevention training (SEPT) to prevent side effects
by optimizing patients’ expectations, which may be an ef-
fective pathway to enhance overall quality of life. This art-
icle describes the study design and the research methods
to answer the following research questions:
1. Is a three-session psychological intervention effective
in reducing side effects and improving quality of life
during long-term intake of endocrine therapy?
2. Do treatment and side-effect expectations mediate
the beneficial effects?
3. Are there certain patient characteristics that predict
which patients benefit the most from the training?
Methods/Design
Study design
The study is designed as dual-center, randomized con-
trolled trial with three arms and follow-up assessment
(see Figure 1). The study procedure is implemented at the
Department of Gynecology, Gynecological Endocrinology
and Oncology, Philipps University Marburg, Germany, and
at the University Medical Center Hamburg-Eppendorf,
Germany. Participants are women with hormone-recep-
tor-positive breast cancer, scheduled to start adjuvant
endocrine treatment. After signing informed consent to
participate in the study and receiving medical informa-
tion about endocrine treatment from the hospital staff,
all patients are provided additional standardized informa-
tion and patient education about the scheduled treatment
by a trained research assistant/ clinical psychologist to
homogenize knowledge about endocrine treatment. The
structured treatment information is given verbally and
through a leaflet, illustrating the physical mode of action,
the desired effects, and the potential side effects of
endocrine therapy. After completing baseline assessment
(including symptom status and pre-treatment side-effect
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Post-treatment assessment (t1)
Figure 1 Study design.
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three groups. Group 1 receives standard medical care
(SMC) only. Group 2 receives SMC and the side-effect
prevention training (SEPT). Group 3 receives SMC and
supportive therapy as an attention control group (ACG).
Outcomes are assessed homogeneously in all three groups,
three and six months after the start of medication intake.
Participants
Patients with hormone-receptor-positive primary breast
cancer scheduled to undergo first-line endocrine treat-
ment with tamoxifen (and additional GnRH-analoga,depending on the menopausal status) or a third-gene-
ration aromatase inhibitor (i.e., anastrozole, letrozole or
exemestan) are eligible. Exclusion criteria are the pres-
ence of a serious co-morbid psychiatric condition (schi-
zophrenia, addiction, severe affective or severe anxiety
disorder), the presence of a life-threatening co-morbid
(non-cancer) medical condition, insufficient German
language skills, and cognitive inability to give informed
consent. Inclusion and exclusion criteria are checked by
screening patients’ history and medical records and stan-
dardized assessment using the structured psychiatric
interview “mini-dips” [36].
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Diagnosis and treatment are initiated independently of
the study according to the German breast cancer guide-
lines by the interdisciplinary tumor board of the breast
cancer center. Patients are required to have completed
primary surgery and/or chemotherapy, if indicated.
Patients are screened for eligibility during their hospital
stay in the breast cancer center. Women meeting the
inclusion criteria are informed about the study concept
and invited by their oncologists to take part in the study.
Patients who give written informed consent after receiving
detailed written and verbal information are admitted to
the study. Participation is voluntary and can be withdrawn
by the patient any time with no disadvantages.
Ethics
The study protocol was approved by the medical ethics
committee of the Philipps University Marburg, and the
Hamburg Medical Chamber. The study will be con-
ducted in accordance with the Declaration of Helsinki,
Good Clinical Practice guidelines, including data and
patients’ privacy protection.
Sample size calculation
Required sample sizes were determined a priori with
G-Power [37]: The sample size for the randomized group
comparison was determined according to a MANOVA
with repeated measures, testing for a three groups x three
time points interaction. Assuming a medium effect size of
f(V)=.20, N=153 patients (n=51 per group) are needed to
achieve 80% power.
Taking into account a potential drop-out rate of 20%
(e.g., due to exhaustion or medical complications), we
aim to include a total of 184 breast cancer patients.
Quality standards (Minimization of bias)
Randomization and blinding
Randomization follows after completing baseline assess-
ment. Patients are equally allocated to one of the three
treatment arms using sealed envelopes. Assignment fol-










Figure 2 Intervention schedule.with a block size of nine. Stratification criteria (2×2) are
the sum score (≤13 vs. >13) of the hospital anxiety and
depression questionnaire (HADS-D) [38,39] during hos-
pital stay and type of medication (aromatase inhibitor
vs. tamoxifen). Assignment sequence is generated by
staff who are not involved in the intervention process
and conducted electronically using the statistical pro-
gram WINPEPI [40]. The research assistants respon-
sible for the assessment are blinded to group allocation.
Attrition bias
In order to examine potential attrition bias, drop-out ana-
lyses will be performed. In accordance with the intention-
to-treat principle, the data of all patients randomised to
the treatment groups will be analysed.
Control for therapeutic allegiance
To ensure the comparability of treatments, treatment
dose, application and assessment occasions for SEPT
and ACG will be identical.
All therapists are clinical psychologists with advanced
cognitive behavioral training and have comparable pro-
fessional experience. They are trained in the use of the
treatment manual before the trial starts. Training in-
cludes a full treatment cycle with at least one patient per
treatment group using video feedback and professional
supervision of each treatment session. During the whole
study therapists are under ongoing supervision by highly
experienced psycho-oncologists. Both types of interven-
tions are manualized and each therapist will treat a com-
parable number of patients in each group. Treatment
fidelity is assessed and rated before approval of thera-
pists to start in this trial. All sessions will be videotaped
and an amount of 33% will be selected randomly and
rated by an independent rater.
Psychological interventions
In the intervention groups three individual sessions of
50–75 minutes are being held with a clinical psycholo-














- Psychoeducation about AET - Knowledge about AET and
nocebo effect
- Guided imagination and visualization
of positive treatment aspects
- Strengthen control and
benefit expectations
- Psychoeducation about nocebo and
non-specific side effects
- Integration of positive aspects
of AET into daily routines
Homework
- Practice relaxation and imagination
(anchored by CD)
- Further creative work with
imagination, e.g., painting
Session 2
- Develop individual problem-solving
scheme for the three most important
side effects
- Optimize coping expectations
- Create an action plan for behavioral
and cognitive strategies
- Reduce specific concerns
Homework
- Complete and modify the personal
problem-solving scheme
- Create an individual “tool box”
- Practice relaxation and imagination
(anchored by CD)
Session 3




- Develop distraction strategies of for
the time of AET intake
- Improving patient-physician
communication
- Summing up and outline treatment
goals
Homework
- Practice relaxation and imagination
(anchored by CD)
- Complete and modify the personal
problem-solving scheme and the
tool box
Telefone booster calls




- Check practicability of the coping
strategies and the “tool box” and
modify if necessary
Notes: AET = Adjuvant endocrine therapy
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telephone calls will be made in both intervention groups.
Intervention: side-effect prevention training
The goal of SEPT is the prevention of non-specific and
nocebo side effects from endocrine therapy by optimi-
zing treatment- and illness-related expectations. Con-
tents of the training are psychoeducation [41] to provide
a realistic view of the treatment, imagination-training to
integrate positive aspects of medication into daily life
and side-effect management [42] to enhance expecta-
tions about individual coping abilities. All intervention
components and goals are listed in Table 1. SEPT is a
manual-based program. Individual topics are adapted
specifically to each patient according to her individual
expectations. The baseline questionnaires are used as a
starting point for tailoring the intervention so it is con-
sistent with the written treatment guidelines. Patients in
the SEPT group receive a booklet with patient material
detailing the contents, goals and interventions of each ses-
sion. The booklet also contains work sheets, postcards
and further material that can be personalized by each par-
ticipant. Sessions will focus on subsequent topics:
Session 1: At the beginning of the first session,
psychoeducation about the active principle of endocrine
treatment is given, tailored to the individual patient’s
needs. The adverse side effects most expected by the
patient are discussed and contrasted with treatment
benefits.
A guided imagination is performed to visualize the
positive aspects (e.g., protection from cancer recur-
rence) of the endocrine treatment. The imagination is
recorded on audio file and incorporated into patients’
daily handling of the medication. Furthermore, the im-
pact of expectations on side effects (e.g., pain following
negative expectations but without the administration of
any inert substance) is discussed and the concept
“nocebo phenomenon” explained to the patients.
Session 2: Session two focuses on the development of
coping strategies for side-effect management that are
implemented in a written problem-solving scheme for
the three most expected or dreaded side effects. Stra-
tegies employed include behavioral techniques, cognitive
strategies, dietary advice, physical exercises, identifica-
tion and avoidance of triggers for specific side effects.
Patients are asked to create a “tool-box” at home filled
with useful material to implement the discussed coping-
strategies.
Session 3: This last session includes skills training for
improved patient-physician communication to positively
influence expectations about breast cancer check-ups.
Additionally, the role of attention for the development
of non-specific side effects and the worsening of specific
side effects is discussed. Patients are encouraged to re(activate) individual resources and activities helping to
distract from the potential occurence of side effects, but
also strenghten the patient for the time of medication
intake. At the end of the session, all topics of the previ-
ous sessions are reviewed.
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the contents of the intervention. The therapeutic contact
is used to give support to the patients during the first
time of medication intake. Many patients describe it as
very helpful to talk about their concerns in this phase of
illness and treatment (the phase of rehabilitation after
being discharged from hospital). During the booster calls,
possible problems with the relaxation and imagination
training are discussed and resolved whenever possible.
The coping strategies are reviewed and adapted. Further-
more, the problem-solving scheme will be extended to
further side effects including new coping strategies.
Attention control group (ACG): supportive therapy
Supportive therapy serves as an attention control group
for non-specific factors such as therapist’s attention and
patient-therapist relationship. It serves to distinguish spe-
cific effects of SEPT from psychological placebo effects
[43]. Supportive therapy [44] as a manualized, non-specific
psychological intervention has been previously used in
clinical trials [45]. It includes common factors such as
elicitation of affect, treatment context, empathy, reflective
listening, and feeling understood. It will be delivered in
the same frequency and on the same occasions as SEPT
(three individual sessions and three booster calls).
Sessions 1, 2 and 3: In the supportive therapy session
contents may vary; there are no specific topics therapists
need to address, there is no patient material and no
homework. Nevertheless, every session can be structured
into three phases: the beginning, the therapeutic dialog
and the end. At the beginning patients are asked about
relevant themes they want to talk about. During the
therapeutic dialog patients lead the session and the
therapist follows, while concentrating especially on the
validation of patients’ affects. It is suggested to talk
about any topics that appear to have an affective valence
to the patients. The therapist focuses on creating a warm
atmosphere and shows empathy and unconditional posi-
tive regard towards the patient. At the ending of all ses-
sions all themes are reviewed with the focus on the
affect of the individual patient.
In the control group booster calls are conducted si-
multaneously to those in the intervention group, but
they do not follow a particular structure. Patients are
asked about their feelings since the last session.
Measures
Assessment occurs at four measurement points (see
Table 2): at baseline approximately two weeks after sur-
gery, after the intervention (post-intervention), and three
and six months after the start of medication intake
(follow-up). Questionnaires are applied by blinded re-
search assistants at all measurement points. The fol-
lowing demographic and medical information will beobtained from medical charts and by baseline-interviews:
socio-demographic status, age, BMI, health status, ac-
companying illnesses and medication (e.g., osteoporosis
and medication), prior experiences with endocrine treat-
ment (hormone contraception, hormone replacement
therapy), stage of disease and tumor characteristics
(UICC-stage, TNM-classification, Grade, ER/PR status,
Her-2-status), type and course of primary treatment
(breast-conserving surgery, mastectomy, radiotherapy,
systemic treatment). Medical follow-up data include
health and disease status, accompanying illnesses and
medication for clinical outcome. All data will be vali-
dated and a plausibility check-up will be conducted.
Primary outcomes
Side effects will be measured with the General Assess-
ment of Side Effects scale (GASE) [46,47] which syste-
matically assesses incidence and intensity of the 36 most
common side effects. To assess the most frequent
patient-reported adverse side effects from endocrine
treatment the scale was modified by adding nine further
symptoms (decreased interest in sex, weight gain, feeling
of tension in breast, mood swings, abdominal bloating,
vaginal dryness, bone fracture, pain during sexual inter-
course, cataract) resulting in a total of 45 symptoms.
Patients will be asked to rate the intensity of each listed
bodily complaint during the past seven days on a four
point Likert scale (0 = “complaint not present”; to
3 = “severe intensity”). Additionally, patients will in-
dicate whether they attribute each of the present symp-
toms to current drug intake. It shows satisfactory
psychometric properties [46].
Secondary outcomes
Quality of life will be assessed with the European
Organization for Research and Treatment of Cancer
Quality of Life Questionnaire (EORTC QLQ-C30) with
breast module (QLQ-BR23) [48]. This questionnaire can
be seen as the standard multidimensional instrument to
measure quality of life among cancer patients. The QLQ-
C30 consists of five functional scales, nine symptom scales
and a global quality-of-life scale. The breast module is com-
posed of eight breast cancer specific scales including four
functional and four symptom scales. Both questionnaires
have demonstrated good psychometric properties [48,49].
Coping ability measures the perceived ability to manage
occurring side effects. It will be accessed via a modified
version of the GASE [46,47] that will ask patients to rate
their coping ability for each of the 45 listed side effects
(i.e., “How good is your ability to manage the occurring
adverse symptom?) on a Likert scale from 0 = “good” to
4 = “bad”.
Medication adherence will be measured with the
German version of the Medication Adherence Report





Follow-up (3 and 6 months after AET
intake)








Physical symptoms and side
effects + coping (GASE+Coping)
x x







Expected side effects + expected
coping (GASE-Expect + * *Coping)
x x x
Illness beliefs (IPQ-B) x x x
Beliefs about medicines (BMQ-D) x x x
Process Variables Fear of progression (PA-F-K) x x x
Anxiety and depression (HADS) x x x










Additional medication x x
Notes:
1The psychiatric interview is conducted prior to the measurement to check the inclusion criteria.
2Completed after every therapy session in the intervention groups only.
von Blanckenburg et al. BMC Cancer 2013, 13:426 Page 7 of 10
http://www.biomedcentral.com/1471-2407/13/426Scale (MARS) [50,51]. This scale gives an indication of
the extent to which non-adherent behaviors occur, in-
cluding how often patients have consciously not taken
their medicines or forgotten to take them. It has been
used to measure the adherence in endocrine treatment
before [52]. Additionally, the adherence intention, the
actual adherence and the attitude towards in cursive
will be assessed with three single items.
Expectations
Side effect expectations refer to the patients’ cognitive
representations of the undesired effects related to a spe-
cific treatment. They will be measured with the General
Assessment of Expected Side Effects Scale (GASE-ex-
pect), which is a modified version of the GASE-scale
[46,47] and was designed to measure patients’ pharma-
cological response expectations with regard to the 45
most common side effects, including non-specific and
specific complaints of endocrine therapy. Patients are
instructed to indicate if and how strongly they expect to
suffer from each potential side effect within the first
three months of endocrine treatment.Self-efficacy expectations about coping refer to the de-
gree to which patients believe they are able to manage
occurring side effects. They will be assessed using a
modified version of the GASE-expect. Patients are asked
to indicate their coping expectations for each of the 45
listed side effects (i.e., “Will I be able to manage occur-
ring adverse symptoms?”).
Treatment expectations: Expectations about medicines
in general as well as specific concerns and necessity beliefs
about endocrine therapy will be assessed with the German
version of the Beliefs About Medicines Questionnaire
(BMQ) [19,50]. The BMQ has previously been used to
assess medications beliefs in breast cancer patients [52].
Additionally, pre-treatment expectations regarding SEPT
and ACG will be assessed using single items.
Illness expectations: Expectations e.g., about time course,
consequences, personal and treatment controllability of
breast cancer, will be measured with the brief illness
perception questionnaire B-IPQ [53]. Each single item
represents a scale (in addition to the above mentioned:
concerns, emotional response, coherence and aspects of
identity). The cause-scale was excluded. This questionnaire
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gested, the words “illness” and “treatment” were replaced
with “breast cancer” and “endocrine therapy” (Table 2).
Additional variables
Fear of progression will be assessed with the short form
of the of the Fear of Progression Questionnaire (PA-F-K)
[55] consisting of 12 statements (e.g., being afraid of
disease progression). It has shown good psychometric
properties in breast cancer patients [56].
Anxiety and depression will be measured with the
German Hospital Anxiety and Depression Scale (HADS-D)
[38,39], which rates the severity of seven symptoms of
anxiety and seven symptoms of depression over the past
week and was designed for use in persons with physical
illnesses. It has shown good psychometric properties in
breast cancer patients [57].
Treatment evaluation will be measured in both inter-
vention groups (ACG and SEPT). After every session,
therapist and patient will rate their satisfaction with the
unit using 12 items.
Knowledge about the patient’s own tumor hormone-
receptor status will be assessed by one item [58].
Somatosensory Amplification is the tendency to per-
ceive ambiguous sensory events as unpleasant and will be
assessed with the Somatosensory Amplification Scale
(SSAS) [59]. The scale consists of 10 items (e.g., “I am
often aware of various things happening within my body”)
and shows high validity and acceptable reliability in sam-
ples with breast cancer [60].
Partnership quality will be measured with one single
item of the short form of the Partnership Questionnaire
(PFB-K) [61] with reference to Terman [62] asking
“How happy would you rate your partnership at the
moment?”, which has been recommended for assessing
satisfaction with a partnership.
Data analysis
Missing values will be replaced using multivariate impu-
tation techniques. A repeated measures multivariate ana-
lysis of variances (MANOVA) will be used to analyze
treatment effects. To identify predictors of treatment
outcome, multiple regression analyses will be conducted.
To analyze pathways of the effects, mediator analyzes
will be computed. Case studies will be performed to
illustrate characteristics of the treatment processes from
patients’ und therapists’ perspectives. Level of signifi-
cance will be set at α = .05.
Baseline demographic data
Preliminary baseline demographic data was assessed in
N = 55 participating women with a primary breast cancer
diagnosis. On average patients were 54.8 years old
(SD=8.2, range=39-71 years), and mostly married or livingwith a partner (61.8%). Other patients were single (12.7%),
widowed (5.5%) or divorced (20.0%). The majority of
patients had primary education (63.6%), other patients
finished secondary education (16.4%) or university educa-
tion (20.0%).
More than half of the patients were diagnosed with stage
I breast cancer (69.1%), further 27.2% of patients were diag-
nosed with stage II and additional 3.6% with stage III. Most
patients (89.1%) received breast conserving therapy and
only 10.9% mastectomy. A large group of patients (69.1%)
was scheduled to undergo first-line endocrine treatment
with tamoxifen (+/− GnRH-analoga). A third generation
aromatase inhibitor (i.e. anastrozole, letrozole or exemestan)
was recommended to the other patients (30.9%).
Discussion
Although expectations have been found to predict the
occurrence of side effects in cancer patients, this study
presents the first randomized controlled trial evaluating a
short-term cognitive-behavioral intervention to prevent
side effects during adjuvant endocrine therapy by optimiz-
ing breast cancer patients’ expectations. The side-effect
prevention training (SEPT) is compared with an attention
control group (ACG) receiving supportive therapy and a
standard medical care group (SMC) receiving standard
treatment for breast cancer patients and additional oral and
written information about adjuvant endocrine treatment.
The primary outcomes are the occurrence of side
effects three and six months after the start of intake of
endocrine therapy. Further beneficial effects for quality
of life, coping ability and adherence to medication are
evaluated. Patients’ response expectations, expecta-
tions about coping ability and expectations about
treatment and illness are analyzed as mediators. The
study also gives some insights into characteristics of
patients who benefit the most from SEPT and of
patients at high risk of developing side effects.
If SEPT is found to be effective, it could be integrated
into daily clinical practice. Effects of preventing non-spe-
cific symtoms and nocebo side effects may improve the
quality of life during treatment, lead to better medication
adherence, and thereby may help to reduce progression
and mortality in breast cancer patients and decrease costs
of treatment. The training could be delivered into health
care settings and applied by trained and supervised health
care professionals. In addition, the study will provide
insights into pathways of clinical nocebo effects and non-
specific side effects that may be applicable to other fields
of illness and medication.
The study has some limitations that need conside-
ration. First, our study design does not allow complete
control regarding information patients may receive from
their gynecologists about side effects of endocrine treat-
ment, coping possibilities and about what happens while
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that the study does not include patients who decide to
start endocrine therapy before the baseline measure-
ment. Presumably, patients in this group experience the
strongest feelings of anxiety of progression and have
more negative illness beliefs. This study does not provide
conclusions about the efficacy of single treatment ele-
ments or differential indications. If treatment effects are
robust, future studies are needed to analyze the particu-
lar influences of those factors.
The optimization of expectations might be a promising
pathway to improve patients’ quality of life during medi-
cation intake. So far, this is the first study investigating a
psychological prevention program for side effects with
the explicit focus on patients’ expectations. The results
will provide implications for a possible integration of
evidence-based prevention training into clinical practice.
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